A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q.
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 03 Dec 2016 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Results (n=49), presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
- 23 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History